FDA approves Novartis high blood pressure drug Tekturna

The FDA gave Novartis AG clearance to market its Tekturna drug to treat high blood pressure, breathing new life into a product the firm had almost given up on seven years ago. Developed with Speedel Holding AG, the drug at one time was considered too expensive to make but now emerges as the first new type of drug in more than a decade for treating high blood pressure.

View Full Article in:

Bloomberg Businessweek · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR